Status:
COMPLETED
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Alzheimer Disease
Eligibility:
All Genders
55-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending I...
Eligibility Criteria
Inclusion
- General
- Body mass index (BMI) between 18 and 35 kilogram per meter square (kg/m\^2), inclusive (BMI = weight/height\^2) and body weight greater than 40 kilogram (kg) but less than 110 kg at screening
- Women must not be of childbearing potential
- Specific Inclusion Criteria Part 2:
- Each potential subject enrolled in Part 2 must satisfy all of the following specific criteria in addition to the general criteria to be enrolled in the study:
- Clinical Dementia Rating Scale (CDR) global rating score of 0.5 or 1.0 at screening
- Must have a reliable informant (example, relative, partner, friend)
- Must have cerebrospinal fluid (CSF) finding consistent with Alzheimer's disease (AD) pathology
Exclusion
- General Exclusion Criteria
- Any potential subject who meets any of the following criteria will be excluded from participating in the study:
- History of or current liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic (including but not limited to neurodegenerative disease (excluding AD for Part 2) \[example, Parkinson's disease\], seizure disorders, transient ischemic attacks, etc.), hematologic (including coagulation disorders), rheumatologic, psychiatric, or metabolic disturbances, any inflammatory illness or any other illness that the Investigator considers should exclude the subject
- Relevant history of or current neurological disease (other than prodromal AD or mild AD for Part 2), which in the opinion of the investigator may make interpretation of possible new neurological signs or symptoms difficult
- History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening (per screening evaluations)
- History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-Hepatitis C virus \[HCV\]) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at screening (per screening evaluations)
- Specific Exclusion Criteria Part 1 - Mini-Mental State Examination (MMSE) score less than or equal to (\<=) 27 at screening
- Specific Exclusion Criteria Part 2
- \- Evidence of brain disease, other than AD, that could explain the cognitive deficit (including, but not limited to, vascular encephalopathy or strokes, as imaged by cerebral Magnetic resonance imaging (MRI)
Key Trial Info
Start Date :
December 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2019
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT03375697
Start Date
December 22 2017
End Date
December 16 2019
Last Update
April 27 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology Unit
Merksem, Belgium, 2170
2
Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie
Bonn, Germany, 53127
3
CTC North GmbH & Co. KG
Hamburg, Germany, 20251
4
Universitätsklinikum des Saarlandes
Homburg / Saar, Germany, 66421